<?xml version="1.0" encoding="UTF-8"?>
<ref id="B118-biomedicines-08-00060">
 <label>118.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Puzanov</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Milhem</surname>
    <given-names>M.M.</given-names>
   </name>
   <name>
    <surname>Minor</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Hamid</surname>
    <given-names>O.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Chastain</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Gorski</surname>
    <given-names>K.S.</given-names>
   </name>
   <name>
    <surname>Anderson</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Chou</surname>
    <given-names>J.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma</article-title>
  <source>J. Clin. Oncol.</source>
  <year>2016</year>
  <pub-id pub-id-type="doi">10.1200/JCO.2016.67.1529</pub-id>
 </element-citation>
</ref>
